Journalism in the Public Interest

Prescriber Checkup

Prescriber Checkup » RITUXAN


Rituximab is a monoclonal antibody. It targets a specific protein on white blood cells that makes it easier for your immune system to find and destroy cancerous cells. It also relieves symptoms and slows the progression of Rheumatoid Arthritis. Source: Iodine  *

*This description is for related drug Rituximab

At a Glance: This Drug in 2013

Medicare Part D Claims

Rank: 1591 of 3238

Retail Cost

Rank: 509 of 3238


Rank: 1521 of 3238


Rank: 1726 of 3238

User Reviews of Related Drug Rituximab »

Information courtesy of

Use by state

State Patients Claims Cost
New York 326 982 $8.15M
California 312 894 $6.92M
Florida 153 509 $3.27M
Texas 145 319 $3.01M
New Jersey 92 240 $2.17M
Pennsylvania 38 117 $882K
Massachusetts 41 115 $938K
Mississippi 17 67 $373K
Ohio 35 61 $655K
Tennessee 13 48 $262K
Connecticut 14 47 $248K
Colorado 43 $199K
Missouri 11 42 $235K
Maryland 36 $278K
Louisiana 13 30 $274K
Nevada 12 29 $231K
Oklahoma 11 25 $338K
Georgia 14 24 $292K
New Mexico 19 $315K
Virginia 16 $123K
North Carolina 16 $101K
Michigan 13 $160K
Illinois 13 $108K
Arizona 13 $247K
About This Data

Prescribing data from Medicare’s prescription drug benefit, known as Part D, was compiled and released by the Centers for Medicare and Medicaid Services, the federal agency that oversees the program. ProPublica combined that data with additional information released by CMS. The data for 2013 includes nearly 1.4 billion prescriptions written by 1.3 million doctors, nurses and other providers. This database lists about 410,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths of these prescriptions went to patients 65 and older; the rest were for disabled patients Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to and we will update your information. If you have other questions about this data, send a note to